Self-propelled biohybrids co-deliver oxaliplatin and glucose oxidase for multimodal treatment of colon cancer
Rattachement africain : cn, de. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
As a frontline chemotherapeutic agent for colorectal cancer, oxaliplatin (OXA) exhibits significantly reduced therapeutic efficacy and may induce severe adverse effects, primarily due to limited targeting capacity and impaired drug penetration within the hypoxic tumor microenvironment (TME). To address this challenge, an iron-based metal-organic framework (MOF) was engineered to co-load OXA and glucose oxidase (GOx). This MOF was subsequently immobilized onto the surface of anaerobic Bifidobacterium infantis (Bif). Leveraging the inherent homing capacity of Bif, a self-propelled biohybrid designated MOGP@Bif was developed. Upon accumulation in tumor tissue, the released components synergistically exert: (i) chemodynamic therapy (CDT) via MOF-mediated generation of hydroxyl radicals through enhanced Fenton reactions between Fe²⁺ and endogenous H₂O₂; (ii) chemotherapy via OXA; (iii) starvation therapy via GOx-mediated glucose depletion. Concurrently, glutathione (GSH) depletion enhances oxidative stress, while OXA-mediated hypoxia amelioration further potentiates tumor cell death. MOGP@Bif significantly prolongs the median survival of CT-26 tumor-bearing mice and reduces OXA-related toxic side effects, achieving an approximately fourfold higher intratumoral OXA concentration compared to free OXA treatment. This bacteria-driven platform represents a promising approach for multimodal solid tumor therapy.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Self-propelled biohybrids co-deliver oxaliplatin and glucose oxidase for multimodal treatment of colon cancer
- Date Crossref
- 01/12/2025
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Affiliated Hospital of Southwest Medical University Department of Oncology pays non établi dans la noticeÉtablissement de santé
-
TUM Klinikum pays non établi dans la noticeÉtablissement de santé
-
Southwest Medical University pays non établi dans la noticeÉtablissement de santé
-
First Affiliated Hospital of Sichuan Medical University pays non établi dans la noticeÉtablissement de santé
-
Technical University of Munich Medicine and health Klinikum rechts der Isar pays non établi dans la noticeUniversité ou école supérieure
Department of Oncology — Affiliated Hospital of Southwest Medical University, TUM Klinikum et Southwest Medical University, avec 2 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.